Jove
Visualize
Contact Us

Related Concept Videos

Mechanical Efficiency of Real Machines01:14

Mechanical Efficiency of Real Machines

The mechanical efficiency of a machine is a fundamental concept that describes how effectively a machine can convert input work into output work. According to this concept, the efficiency of a machine is equal to the ratio of the output work to the input work. An ideal machine, meaning a machine that has no energy losses, has an efficiency of one. This implies that the input work and the output work are equal.
However, in reality, no machine can be truly ideal, and all of them experience some...
Turnover Number and Catalytic Efficiency01:19

Turnover Number and Catalytic Efficiency

The turnover number of an enzyme is the maximum number of substrate molecules it can transform per unit time. Turnover numbers for most enzymes range from 1 to 1000 molecules per second. Catalase has the known highest turnover number, capable of converting up to 2.8×106 molecules of hydrogen peroxide into water and oxygen per second. Lysozyme has the lowest known turnover number of half a molecule per second.
Chymotrypsin is a pancreatic enzyme that breaks down proteins during digestion. The...
Production Efficiency01:01

Production Efficiency

Net production efficiency (NPE) is the efficiency at which organisms assimilate energy into biomass for the next trophic level. Due to low metabolic rates and less energy spent on thermoregulatory processes, the NPE of ectotherms (cold-blooded animals) is 10 times higher than endotherms (warm-blooded animals).
Catalytically Perfect Enzymes01:07

Catalytically Perfect Enzymes

The theory of catalytically perfect enzymes was first proposed by W.J. Albery and J. R. Knowles in 1976. These enzymes catalyze biochemical reactions at high-speed. Their catalytic efficiency values range from 108-109 M-1s-1. These enzymes are also called 'diffusion-controlled' as the only rate-limiting step in the catalysis is that of the substrate diffusion into the active site. Examples include triose phosphate isomerase, fumarase, and superoxide dismutase.
Kinetic Energy - II00:56

Kinetic Energy - II

The kinetic energy of a particle is one-half of the product of the particle’s mass and the square of its speed. Note that just as Newton’s second law can be expressed as either the rate of change of momentum or mass multiplied by the rate of change of velocity, so too can the kinetic energy of a particle be expressed in terms of its mass and momentum, instead of its mass and velocity.
Enzyme Kinetics01:19

Enzyme Kinetics

Enzymes speed up reactions by lowering the activation energy of the reactants. The speed at which the enzyme turns reactants into products is called the rate of reaction. Several factors impact the rate of reaction, including the number of available reactants. Enzyme kinetics is the study of how an enzyme changes the rate of a reaction.
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers.

Cancer discovery·2026
Same author

Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.

Cancer discovery·2025
Same author

Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers.

Cell chemical biology·2025
Same author

A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumors.

Science (New York, N.Y.)·2025
Same author

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.

Journal of medicinal chemistry·2025
Same author

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers.

Journal of medicinal chemistry·2025
Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026
Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 29, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

Kinetic efficiency: the missing metric for enhancing compound quality?

Geoffrey A Holdgate1, Adrian L Gill

  • 1Structure & Biophysics, Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom. geoff.holdgate@astrazeneca.com

Drug Discovery Today
|September 28, 2011
PubMed
Summary
This summary is machine-generated.

Drug discovery benefits from understanding ligand-target interaction kinetics. A new metric, kinetic efficiency, aids in identifying compounds with unique kinetic properties, enhancing drug development quality.

More Related Videos

Improving the Combustion Performance of a Hybrid Rocket Engine using a Novel Fuel Grain with a Nested Helical Structure
07:58

Improving the Combustion Performance of a Hybrid Rocket Engine using a Novel Fuel Grain with a Nested Helical Structure

Published on: January 18, 2021

Related Experiment Videos

Last Updated: May 29, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

Improving the Combustion Performance of a Hybrid Rocket Engine using a Novel Fuel Grain with a Nested Helical Structure
07:58

Improving the Combustion Performance of a Hybrid Rocket Engine using a Novel Fuel Grain with a Nested Helical Structure

Published on: January 18, 2021

Area of Science:

  • Pharmacology and Drug Discovery
  • Biophysics
  • Computational Chemistry

Background:

  • Ligand-target interaction kinetics are crucial for drug efficacy.
  • Advancements in label-free methods enable kinetic parameter measurement.
  • Metrics like ligand efficiency and enthalpic efficiency are used to assess compound quality.

Purpose of the Study:

  • Introduce a novel metric, kinetic efficiency, for evaluating drug compounds.
  • Propose a pragmatic approach to identify compounds with differentiated kinetic behavior.
  • Enhance decision-making processes in drug discovery for higher quality compounds and series.

Main Methods:

  • Utilizing label-free methodologies for measuring kinetic parameters.
  • Employing established metrics such as ligand efficiency and enthalpic efficiency.
  • Developing and applying the proposed kinetic efficiency metric.

Main Results:

  • Kinetic efficiency provides a new way to assess compound behavior.
  • The combination of kinetic efficiency with other metrics can improve compound selection.
  • This approach supports the identification of superior drug candidates.

Conclusions:

  • Kinetic efficiency is a valuable metric for drug discovery.
  • Integrating kinetic efficiency enhances the selection of high-quality compounds.
  • This metric contributes to more effective drug development strategies.